Shares of Voyager Therapeutics Inc.
VYGR,
+10.65%

rallied 35% in premarket trading on Monday after the company announced a deal with Neurocrine Biosciences Inc.
NBIX,
+0.06%

to develop and commercialize gene therapies, including one that is being tested as a treatment for Parkinson’s disease. Neurocrine will make a $175 million upfront payment, including a $39 million equity investment, with up to $1.5 billion in potential milestones. Voyager’s stock has soared 148.7% over the past year, while the S&P 500
SPX,
+2.28%

is down 17.0%.

Source link

You May Also Like

Microsoft Hires Sam Altman Following OpenAI Departure | Entrepreneur

The dramatic cycle of firing, hiring, and change at Open AI has…

Entrepreneur Magazine: Finding Motivation In The Face of Setbacks | Entrepreneur

You’re trying to get somewhere. But you’re not there yet. That is…

Sony is making a bold bet on an African gaming startup to boost PlayStation’s reach in the continent

The PlayStation DualSense controller and PlayStation 5 console. Jakub Porzycki | Nurphoto…

Sale of Manchester United Highlights Pricey Bets on Soccer

The big money in pro soccer While American sports teams have been…